Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

The company is reportedly seen as an attractive acquisition target due to its diversified operations across two segments.

SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.

PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin ...

Fennec Pharma’s partner Norgine Pharma launches Pedmarqsi in Germany: Monday, February 10, 2025, 14:00 Hrs [IST] Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, ...

the German pharma and technology company said on Thursday. Merck raises outlook for electronics and healthcare, sees improved chip market demand Germany's Merck on Friday raised its forecast for ...

X-Elio will supply 245GWh of clean energy annually to four pharmaceutical companies through its Lorca Solar project.

G2G Bio partners with Boehringer Ingelheim to develop long-lasting injectable drug G2G Bio collaborates with Boehringer Ingelheim to innovate in injectable drug development ...

From the beginning of 2025, Section 130b of book five of the German Social Code (Sozialgesetzbuch Fünftes Buch, SGB5), which contains regulations on price negotiations between the pharmaceutical ...

(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") ...